As the Houston Texans cleared out their lockers on Monday, they made it abundantly clear they want Stefon Diggs in that locker room next season. Diggs, an All-Pro receiver, is an unrestricted ...

Houston Texans wide receiver Stefon Diggs has faced growing speculation about where he could land next season, but the All-Pro was embroiled in a different kind of rumor this week. Diggs was ...

Houston Texans wide receiver Stefon Diggs is set to become a free agent this offseason after his first year with the Texans, but quarterback C.J. Stroud would "love" for Diggs to return next season.

Last spring, the Houston Texans rocked the NFL landscape when they acquired Stefon Diggs in a blockbuster trade with the Buffalo Bills. The minute the Texans landed Diggs, they were widely viewed ...

They lost Tank Dell to a devastating knee injury a few weeks ago, and of course they also lost their major offseason acquisition, Stefon Diggs, earlier in the year. And if C.J. Stroud has his way ...

Houston Texans quarterback C.J. Stroud lobbied for the team to retain wide receiver Stefon Diggs, who is heading to free agency this offseason. Stroud told reporters Monday he'd "love" to have ...

Gabby Jones / Bloomberg / Getty Images Johnson & Johnson is scheduled to report fourth-quarter earnings Wednesday morning, with analysts expecting sales and profits to grow year-over-year.

The Texans' season came to an end on Saturday afternoon in Kansas City, but quarterback C.J. Stroud hopes his time as Stefon Diggs' teammate doesn't end there. Houston held their end-of-season ...

Jimmy Johnson hinted at his potential retirement while tearing up during an emotional segment honoring his coaching career during the Fox pregame show for Super Bowl 2025. The segment included a ...

It’s nearly a year and a half since Johnson & Johnson split off its consumer-health arm to focus on pharmaceuticals and medical technology. Johnson & Johnson has wasted no time expanding its ...

Bryan Johnson, a tech entrepreneur, has stopped using rapamycin, a drug not approved for anti-aging by the FDA, following concerns it may have aged him and caused infections. Johnson experienced ...

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the ...